Rabeprazole sodium is the active pharmaceutical ingredient (API) for rabeprazole, a medication used to treat conditions related to excess stomach acid [1]. It belongs to a class of drugs known as proton pump inhibitors (PPIs) [2].
How does rabeprazole sodium work?
Rabeprazole sodium functions by irreversibly inhibiting the H+/K+-ATPase enzyme system, commonly referred to as the proton pump, located in the gastric parietal cells [3]. This action effectively reduces the secretion of stomach acid [2][3].
What conditions does rabeprazole sodium treat?
Rabeprazole sodium is indicated for the treatment of various acid-related gastrointestinal disorders, including:
* Gastroesophageal reflux disease (GERD) [2]
* Erosive esophagitis [2]
* Healing of duodenal ulcers [2]
* Pathological hypersecretory conditions, such as Zollinger-Ellison syndrome [2]
When does rabeprazole sodium's patent protection end?
Information regarding specific patent expiry dates for rabeprazole sodium API can be found on resources like DrugPatentWatch.com [4]. Patent protection for pharmaceutical compounds is complex, involving multiple patents that can cover the composition of matter, manufacturing processes, and methods of use [4].
Who manufactures rabeprazole sodium API?
Various pharmaceutical companies globally are involved in the manufacturing of rabeprazole sodium API. These include both originator companies and generic manufacturers [5]. Access to a comprehensive list of manufacturers and their associated patents is available through specialized databases.
What is the difference between rabeprazole and rabeprazole sodium?
Rabeprazole is the active drug substance, while rabeprazole sodium is the sodium salt form of rabeprazole [1]. Salt forms are often used in pharmaceutical formulations to improve properties such as solubility, stability, and bioavailability [1].